Sehn, Laurie H.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., et al. (2007) · Blood

Lymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and Treatment

Cited by 1,473

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., et al. (2018) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 373

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery

Lymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 318

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting

Sehn, L. H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K. K., Runzer, N., Searle, B., Souliere, S., Spinelli, J. J., Sutherland, J., et al. (2007) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 100

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 94

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Sehn, L. H., Hübel, K., Luminari, S., Scholz, C. W., Salar, A., Paneesha, S., Wahlin, B. E., Panayiotidis, P., Lee, H.-P., Jiménez-Ubieto, A., et al. (2026) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 25

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Li, C.-C., Bender, B., Yin, S., Li, Z., Zhang, C., Hernandez, G., Kwan, A., Sun, L., Adamkewicz, J. I., Wang, H., et al. (2019) · Blood

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 14